99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer - Trial NCT06419348
Access comprehensive clinical trial information for NCT06419348 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on Prostate Cancer Stage,PSMA,SPECT. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital of Chongqing Medical University
Timeline & Enrollment
Phase 1
May 20, 2024
Dec 31, 2026
Primary Outcome
Diagnostic efficacy
Summary
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent
 imaging agent applicable to PSMA positive prostate cancer. In this study, we will investigate
 the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for
 the diagnosis of lesions in PSMA positive prostate cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419348
Non-Device Trial